Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 8Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 44Cyclophosphamide 21Nivolumab 18fludarabine 10durvalumab 8Paclitaxel 8Magnetic Resonance Spectroscopy 8Interleukin-2 8Docetaxel 8aldesleukin 7Radiosurgery 7Ipilimumab 7spartalizumab 6poly ICLC 6fludarabine phosphate 6atezolizumab 6Specimen Handling 6Radiotherapy 6Carboplatin 6cemiplimab 5Drug Therapy 5Cisplatin 5Biopsy 5Temozolomide 4Immune Checkpoint Inhibitors 4tremelimumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 3pazopanib 3avelumab 3Trastuzumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × MLN 8237 × Breast × Clear all
NCT01639911 2019-07-22

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

University of Illinois at Chicago

Phase 1 Completed
28 enrolled
BreastCNSDermatologicGastrointestinalHead & Neck

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Melanoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡